Anna Planagumà

1.9k total citations
23 papers, 1.3k citations indexed

About

Anna Planagumà is a scholar working on Pharmacology, Biochemistry and Physiology. According to data from OpenAlex, Anna Planagumà has authored 23 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 7 papers in Biochemistry and 6 papers in Physiology. Recurrent topics in Anna Planagumà's work include Inflammatory mediators and NSAID effects (8 papers), Eicosanoids and Hypertension Pharmacology (7 papers) and Liver physiology and pathology (5 papers). Anna Planagumà is often cited by papers focused on Inflammatory mediators and NSAID effects (8 papers), Eicosanoids and Hypertension Pharmacology (7 papers) and Liver physiology and pathology (5 papers). Anna Planagumà collaborates with scholars based in Spain, United States and United Kingdom. Anna Planagumà's co-authors include Joan Clària, Vicente Arroyo, Marta López‐Parra, Esther Titos, Rosa Miquel, Ana González‐Périz, Bruce D. Levy, Juan Rodés, Raquel Horrillo and Natàlia Ferré and has published in prestigious journals such as Gastroenterology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Anna Planagumà

23 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Planagumà Spain	16	352	299	292	275	258	23	1.3k
Raquel Horrillo Spain	15	568 1.6×	508 1.7×	347 1.2×	332 1.2×	321 1.2×	24	1.3k
José Alcaraz‐Quiles Spain	17	441 1.3×	306 1.0×	317 1.1×	248 0.9×	242 0.9×	23	1.1k
Bibiana Rius Spain	20	667 1.9×	587 2.0×	473 1.6×	457 1.7×	417 1.6×	23	1.7k
Shamsuddin Khwaja United States	16	255 0.7×	170 0.6×	212 0.7×	285 1.0×	129 0.5×	25	1.1k
Marcos Martínez‐Clemente Spain	10	761 2.2×	590 2.0×	382 1.3×	500 1.8×	413 1.6×	12	1.6k
Eva Morán‐Salvador Spain	14	968 2.8×	674 2.3×	451 1.5×	653 2.4×	507 2.0×	16	2.0k
Verónica García‐Alonso Spain	12	628 1.8×	330 1.1×	371 1.3×	416 1.5×	377 1.5×	12	1.3k
Ronald G. Thurman United States	12	705 2.0×	163 0.5×	223 0.8×	522 1.9×	151 0.6×	16	1.5k
Cristina López‐Vicario Spain	28	1.2k 3.5×	683 2.3×	591 2.0×	755 2.7×	568 2.2×	44	2.6k
Marika Collin United Kingdom	19	171 0.5×	87 0.3×	217 0.7×	633 2.3×	183 0.7×	24	1.3k

Countries citing papers authored by Anna Planagumà

Since Specialization

Citations

This map shows the geographic impact of Anna Planagumà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Planagumà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Planagumà more than expected).

Fields of papers citing papers by Anna Planagumà

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Planagumà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Planagumà. The network helps show where Anna Planagumà may publish in the future.

Co-authorship network of co-authors of Anna Planagumà

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Planagumà. A scholar is included among the top collaborators of Anna Planagumà based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Planagumà. Anna Planagumà is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orellana, Adelina, Vicente García‐González, Rosa López-Gigosos, et al.. (2018). Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells. PLoS ONE. 13(1). e0189247–e0189247. 8 indexed citations

Planagumà, Anna, Teresa Domènech, Elena Calama, et al.. (2015). Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation. Pulmonary Pharmacology & Therapeutics. 34. 37–45. 37 indexed citations

Kazani, Shamsah, Anna Planagumà, Emiko Ono, et al.. (2013). Exhaled breath condensate eicosanoid levels associate with asthma and its severity. Journal of Allergy and Clinical Immunology. 132(3). 547–553. 84 indexed citations

Planagumà, Anna, Teresa Domènech, Israel Ramos, et al.. (2013). Lack of activity of 15-epi-lipoxin A4 on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function. Clinical & Experimental Immunology. 173(2). 298–309. 15 indexed citations

Planagumà, Anna, Michael A. Pfeffer, George Rubin, et al.. (2010). Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunology. 3(3). 270–279. 83 indexed citations

Ferré, Natàlia, Marcos Martínez‐Clemente, Marta López‐Parra, et al.. (2009). Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. American Journal of Physiology-Gastrointestinal and Liver Physiology. 296(3). G553–G562. 64 indexed citations

Planagumà, Anna, Shamsah Kazani, Gautham Marigowda, et al.. (2008). Airway Lipoxin A4 Generation and Lipoxin A4 Receptor Expression Are Decreased in Severe Asthma. American Journal of Respiratory and Critical Care Medicine. 178(6). 574–582. 186 indexed citations

López‐Parra, Marta, Esther Titos, Raquel Horrillo, et al.. (2008). Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. Journal of Lipid Research. 49(12). 2513–2523. 45 indexed citations

Planagumà, Anna & Bruce A. Levy. (2008). Uncontrolled airway infl ammation in lung disease represents a defect in counter-regulatory signaling. PubMed. 3(6). 697–704. 10 indexed citations

10.

Horrillo, Raquel, Anna Planagumà, Ana González‐Périz, et al.. (2007). Comparative Protection against Liver Inflammation and Fibrosis by a Selective Cyclooxygenase-2 Inhibitor and a Nonredox-Type 5-Lipoxygenase Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 323(3). 778–786. 48 indexed citations

11.

López‐Parra, Marta, Esther Titos, Anna Planagumà, et al.. (2006). Gene expression profiling of renal dysfunction in rats with experimental cirrhosis. Journal of Hepatology. 45(2). 221–229. 3 indexed citations

12.

Clària, Joan & Anna Planagumà. (2005). Liver: The formation and actions of aspirin-triggered lipoxins. Prostaglandins Leukotrienes and Essential Fatty Acids. 73(3-4). 277–282. 14 indexed citations

13.

Titos, Esther, Joan Clària, Anna Planagumà, et al.. (2005). Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. Journal of Leukocyte Biology. 78(4). 871–878. 51 indexed citations

14.

Planagumà, Anna, Joan Clària, Rosa Miquel, et al.. (2005). The selective cyclooxygenase‐2 inhibitor SC‐236 reduces liver fibrosis by mechanisms involving non‐parenchymal cell apoptosis and PPARγ activation. The FASEB Journal. 19(9). 1120–1122. 114 indexed citations

15.

López‐Parra, Marta, Joan Clària, Esther Titos, et al.. (2004). The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARγ. Influence of albumin. Journal of Hepatology. 42(1). 75–81. 17 indexed citations

16.

Titos, Esther, Anna Planagumà, Neus Villamor, et al.. (2004). 5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis. PubMed. 3(S1). S19–S19. 3 indexed citations

17.

Planagumà, Anna, Joan Clària, Marta López‐Parra, et al.. (2004). 21 The selective cyclooxygenase-2 inhibitor SC-236 reduces experimental liver fibrosis by inactivating kupffer cells and acting as a peroxisome proliferator-activated receptor gamma ligand. Journal of Hepatology. 40. 8–9. 1 indexed citations

18.

Titos, Esther, Joan Clària, Anna Planagumà, et al.. (2003). Inhibition of 5‐lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. The FASEB Journal. 17(12). 1745–1747. 65 indexed citations

19.

López‐Parra, Marta, Joan Clària, Anna Planagumà, et al.. (2002). Cyclooxygenase‐1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. British Journal of Pharmacology. 135(4). 891–900. 35 indexed citations

20.

Velasco, Josefa Ros, Joan Clària, Jordi To‐Figueras, et al.. (2002). Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 122(1). 85–93. 168 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact